| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease.
NEW YORK, March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer's disease therapeutic. Targeting the Substance P/Neurokinin 1 Receptor pathway, HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease.
This pioneering study, conducted by a distinguished team of researchers including Carla Yuede, Kate M. Reardon, Ryan T. Harrigan, and John R. Cirrito, among others, highlights HT-ALZ's profound impact on Alzheimer's pathology. By specifically antagonizing the NK1 receptor, HT-ALZ not only reduces soluble Aβ levels in the brain's interstitial fluid but also significantly diminishes anxiety-like behavior and enhances cognitive function in preclinical models.
The research presents compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment. While the effects on plaque deposition and Aβ levels were inconclusive, the treatment's cognitive benefits suggest that HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients.
HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subjects suffering from Alzheimer's disease, offering a beacon of hope.
Hoth Therapeutics remains committed to further research and development of HT-ALZ, including detailed analyses of its effects on microglial activation and brain inflammation. The company is optimistic about HT-ALZ's path toward. The full manuscript of the study will be published later this year and we look forward to a presentation of the results by the scientists named above who will be sharing this data at an Alzheimer's Research Center group at Washington University in St Louis.
For more information on Hoth Therapeutics and our innovative approach to Alzheimer's disease treatment with HT-ALZ, please visit https://hoththerapeutics.com
Posted In: HOTH
